[HTML][HTML] PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
L Jiang, X Su, T Zhang, X Yin, M Zhang, H Fu, H Han… - Oncotarget, 2017 - ncbi.nlm.nih.gov
L Jiang, X Su, T Zhang, X Yin, M Zhang, H Fu, H Han, Y Sun, L Dong, J Qian, Y Xu, X Fu…
Oncotarget, 2017•ncbi.nlm.nih.govIn order to explore the potential patient population who could benefit from anti PD-1/PD-L1
mono or combination therapies, this study aimed to profile a panel of immunotherapy related
biomarkers (PD-1, PD-L1, CTLA-4 and CD8) and targeted therapy biomarkers (EGFR,
KRAS, ALK, ROS1 and MET) in NSCLC.
mono or combination therapies, this study aimed to profile a panel of immunotherapy related
biomarkers (PD-1, PD-L1, CTLA-4 and CD8) and targeted therapy biomarkers (EGFR,
KRAS, ALK, ROS1 and MET) in NSCLC.
Abstract
In order to explore the potential patient population who could benefit from anti PD-1/PD-L1 mono or combination therapies, this study aimed to profile a panel of immunotherapy related biomarkers (PD-1, PD-L1, CTLA-4 and CD8) and targeted therapy biomarkers (EGFR, KRAS, ALK, ROS1 and MET) in NSCLC.
ncbi.nlm.nih.gov
